Search

Helping steer EHA into the future

In 2020, EHA launched the Taskforce on Diversity, Equity, and Inclusion with an EHA Board mandate.

Read more

EU Parliament agrees on pharmaceutical legislation stance

On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.

Read more

Publications

For the subgroup Rare hereditary blood cancers:
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.

Read more

Restrictions

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed.

Read more

SWG Educational Activities

2023 was a brainstorming year for the SWG.

Read more

EHA-SWG Scientific Meeting on Acquired Aplastic Anemia

EHA & the EHA Scientific Working Group on Granulocyte and Constitutional Marrow Failure Syndromes are happy to announce their recent collaboration in organizing a virtual meeting program on Acquired Aplastic Anemia.

Read more

Kite and Gilead @EHA25 Virtual

We are proud to support the first ever EHA25 Virtual congress. Please join us & leading experts to learn about the latest in cell therapies and COVID-19.

Read more

The ‘i4MDS’ consortium looks to the future at its second general meeting

Feb 29 2024 Posted in Meeting reports Tagged i4MDS

The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.

Read more